zinsinus,
The stock price of biotechs is usually 6x-10x sales. Genentech is about the only established company I can think of trading closer to 12x sales. Even at 6x sales, the share price has a whole lot of room to move up based on io_io's sales estimates. Io_io knows much more about DOR than I do, so I would value his sales estimate. Of course, there is more to DOR than OrBec. The risk/reward ration here is unbelievable, IMHO.
Best regards,
Geoff
Market Data 
Markets 
AI
